Search results for "CANDIDA"

showing 10 items of 844 documents

A Naturally Occurring Antibody Fragment Neutralizes Infectivity of Diverse Infectious Agents

2016

AbstractA phosphorylated peptide, named K40H, derived from the constant region of IgMs was detected in human serum by liquid chromatography coupled to high-resolution mass spectrometry. Synthetic K40H proved to exert a potent in vitro activity against fungal pathogens, and to inhibit HIV-1 replication in vitro and ex vivo. It also showed a therapeutic effect against an experimental infection by Candida albicans in the invertebrate model Galleria mellonella. K40H represents the proof of concept of the innate role that naturally occurring antibody fragments may exert against infectious agents, shedding a new light upon the posthumous role of antibodies and opening a new scenario on the multif…

0301 basic medicineMicrobial Sensitivity TestsVirus ReplicationArticleMass SpectrometryMicrobiology03 medical and health sciencesAnti-Infective AgentsCandida albicansHumansPhosphorylationCandida albicansInfectivityMultidisciplinaryInnate immune system030102 biochemistry & molecular biologybiologybiology.organism_classificationVirologyPeptide FragmentsIn vitroImmunoglobulin Fc FragmentsGalleria mellonella030104 developmental biologyImmunoglobulin MHumoral immunityHIV-1biology.proteinAntibodyEx vivoChromatography LiquidScientific Reports
researchProduct

Evaluation of a novel chromogenic medium for Candida spp. identification and comparison with CHROMagar™ Candida for the detection of Candida auris in…

2020

Abstract A shift to Candida non-albicans infections has been noted during the last years, and the emergence of multi-resistant Candida auris has complicated their management. The aim of this study was first to compare the performance of the novel chromogenic medium CHROMagar™ Candida Plus (CHROMagar, France) with CHROMagar™ Candida (Becton Dickinson, Germany) for the presumptive identification of Candida species; and then, to evaluate its utility in the detection of C. auris in surveillance samples. CHROMagar™ Candida Plus showed a good performance compared with the reference medium CHROMagar™ Candida. Sensitivity and specificity were 100% in both media for tested species at 48 h of incubat…

0301 basic medicineMicrobiology (medical)030106 microbiologySensitivity and SpecificityMicrobiology03 medical and health sciencesfluids and secretions0302 clinical medicineHumans030212 general & internal medicineMycological Typing TechniquesCandidaCandida glabratabiologyChromogenicCandida lusitaniaeBecton dickinsonCandidiasisGeneral Medicinebacterial infections and mycosesequipment and suppliesbiology.organism_classificationCulture MediaInfectious DiseasesCandida aurisChromogenic CompoundsCandida sppChromagar candidaDiagnostic microbiology and infectious disease
researchProduct

Candida auris: An Overview of How to Screen, Detect, Test and Control This Emerging Pathogen

2020

The multidrug-resistant yeast Candida auris is associated with invasive infections in critically ill patients and has been isolated in different countries worldwide. Ease of spread, prolonged persistence in the environment and antifungal drug resistance pose a significant concern for the prevention of transmission and management of patients with C. auris infections. Early and correct identification of patients colonized with C. auris is critical in containing its spread. However, this may be complicated by C. auris strains being misidentified as other phylogenetically related pathogens. In this review, we offer a brief overview highlighting some of the critical aspects of sample collection,…

0301 basic medicineMicrobiology (medical)<i>Candida auris</i><i>Candida auris</i> identification030106 microbiologyAntifungal drugReviewBiochemistryMicrobiologyMicrobiology03 medical and health sciencesEmerging pathogenMedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsTransmission (medicine)business.industryCritically illscreeningantifungal resistance testinglcsh:RM1-950Candida aurisCandida auris identificationlcsh:Therapeutics. Pharmacology030104 developmental biologyInfectious DiseasesCandida aurisSample collectionbusinessAntibiotics
researchProduct

H89 Treatment Reduces Intestinal Inflammation and Candida albicans Overgrowth in Mice

2020

Deregulation of the dynamic crosstalk between the gut microbiota, intestinal epithelial cells, and immune cells is critically involved in the development of inflammatory bowel disease and the overgrowth of opportunistic pathogens, including the human opportunistic fungus Candida albicans. In the present study, we assessed the effect of N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89), a protein kinase A inhibitor, on the migration of macrophages to C. albicans through dextran sulphate sodium (DSS)-challenged Caco-2 cells. We also investigated the impact of H89 on intestinal inflammation and C. albicans clearance from the gut, and determined the diversity of the gut microbio…

0301 basic medicineMicrobiology (medical)<i>Lactobacillus johnsonii</i>colitisH89030106 microbiologyInflammationGut floraMicrobiologydigestive systemArticleMicrobiology03 medical and health sciences<i>Enterococcus faecalis</i>Immune system[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesVirologyCandida albicansmedicineEscherichia coliEnterococcus faecalismicrobiotaColitisCandida albicanslcsh:QH301-705.5Lactobacillus johnsoniiLactobacillus johnsoniiDSSH89;Candida albicans;Escherichia coli;Enterococcus faecalis;Lactobacillus johnsonii;microbiota;DSS;colitis;protein kinase AInnate immune systembiology<i>Escherichia coli</i>[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseasebiology.organism_classificationCorpus albicans3. Good health<i>Candida albicans</i>030104 developmental biologylcsh:Biology (General)[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacologyprotein kinase Amedicine.symptomMicroorganisms
researchProduct

In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species

2016

Objectives: To evaluate the in vitro activity of anidulafungin combined with amphotericin B or voriconazole against Candida spp. biofilms. Methods: Four Candida albicans, four Candida tropicalis, four Candida glabrata, two Candida parapsilosis and two Candida orthopsilosis blood isolates were tested by the microdilution chequerboard method combined with the XTT metabolic assay. Biofilm MIC was defined as the lowest concentration producing 50% metabolic inhibition with respect to control (BMIC50). Concentrations in the combinations ranged from 1/8xBMIC(50) to 4xBMIC(50) found for each antifungal tested alone. Results: Anidulafungin plus amphotericin B acted synergistically against C. albican…

0301 basic medicineMicrobiology (medical)Antifungal Agents030106 microbiologyMicrobial Sensitivity TestsCandida parapsilosisAnidulafunginMicrobiologyCandida tropicalis03 medical and health sciencesEchinocandinsAmphotericin BAmphotericin BmedicineHumansPharmacology (medical)Candida albicansCandidaPharmacologyVoriconazolebiologyCandida glabrataChemistryCandidemiaDrug Synergismbiology.organism_classificationbacterial infections and mycosesCorpus albicansInfectious DiseasesBiofilmsAnidulafunginVoriconazolemedicine.drug
researchProduct

(1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study.

2016

OBJECTIVES To determine the effects of a strategy that uses serum (1,3)-β-d-glucan (BDG) results for antifungal treatment of ICU patients at high risk of invasive candidiasis. PATIENTS AND METHODS Adult patients admitted to the ICU from January 2012 to June 2014 were included if they exhibited sepsis at the time of BDG testing and they met Candida score components ≥3. A retrospective analysis of collected data was performed. RESULTS In total, 198 patients were studied. Of 63 BDG-positive patients, 47 with candidaemia and 16 with probable Candida infection, all [31.8% (63/198)] received antifungal therapy. Of 135 BDG-negative patients, 110 [55.5% (110/198)] did not receive antifungal therapy…

0301 basic medicineMicrobiology (medical)AntifungalAdultMalemedicine.medical_specialtyAntifungal AgentsAntigens Fungalbeta-GlucansLetterAdolescentMedicine (all); Pharmacology; Infectious Diseases; Pharmacology (medical)medicine.drug_classCritical Illness030106 microbiologyAntifungal drugSettore MED/17 - MALATTIE INFETTIVESettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICAlaw.inventionSepsis03 medical and health sciencesYoung AdultlawInternal medicineSepsismedicineHumansPharmacology (medical)Candidiasis InvasiveMedical prescriptionYoung adultCandidaAgedRetrospective StudiesPharmacologyAged 80 and overbusiness.industryMedicine (all)Retrospective cohort studyMiddle Agedmedicine.diseaseIntensive care unitSurgeryInfectious DiseasesObservational studyFemaleProteoglycansbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Invasive candida infections in neonates after major surgery: Current evidence and new directions

2021

Infections represent a serious health problem in neonates. Invasive Candida infections (ICIs) are still a leading cause of mortality and morbidity in neonatal intensive care units (NICUs). Infants hospitalized in NICUs are at high risk of ICIs, because of several risk factors: broad spectrum antibiotic treatments, central catheters and other invasive devices, fungal colonization, and impaired immune responses. In this review we summarize 19 published studies which provide the prevalence of previous surgery in neonates with invasive Candida infections. We also provide an overview of risk factors for ICIs after major surgery, fungal colonization, and innate defense mechanisms against fungi, a…

0301 basic medicineMicrobiology (medical)Antifungalmedicine.medical_specialtymedicine.drug_classInvasive Candida infections030106 microbiologylcsh:MedicineInvasive Candida infectionCandida infections03 medical and health sciencesBroad spectrumNeonatal surgeryinvasive <i>Candida</i> infections0302 clinical medicineInvasive fungal infectionInvasive fungal infectionsIntensive careEpidemiologyFungal colonizationImmunology and AllergyMedicineAntifungal prophylaxi030212 general & internal medicineMolecular BiologyNewbornsGeneral Immunology and Microbiologybusiness.industrylcsh:RImpaired immune responsesNewbornSurgeryNeonatal surgeryInfectious DiseasesSettore MED/20SurgeryAntifungal prophylaxisAntifungal prophylaxis; Invasive Candida infections; Invasive fungal infections; Neonatal surgery; Newborns; Surgerybusiness
researchProduct

In Vitro Antimicrobial Activity of Frankincense Oils from Boswellia sacra Grown in Different Locations of the Dhofar Region (Oman)

2020

Frankincense essential oils from Boswellia sacra have been commonly used to treat microbial infections from as early as the 11th century. The main feature of the plant is its gum resin, from which it is possible to obtain essential oils. In the present study, we focused on the comparative study of the oils extracted from the resins of three different Boswellia sacra cultivars (Najdi, Sahli and Houjri). From each of frankincense resin three successive essential oil samples (Grade 1, Grade 2, Grade 3) were obtained. Houjri gum resin gave the lowest percentage (5%) of total essential oil content but showed the maximum number of volatile components in all three grades. Najdi Grade 2 essential o…

0301 basic medicineMicrobiology (medical)Candida albicanStaphylococcus aureusmedicine.disease_causeSettore BIO/19 - Microbiologia Generale01 natural sciencesBiochemistryMicrobiologylaw.invention03 medical and health sciencesPropionibacterium acnesMinimum inhibitory concentrationlawPropionibacterium acneCandida albicansmedicinePharmacology (medical)Propionibacterium acnesGeneral Pharmacology Toxicology and PharmaceuticsCandida albicansEssential oilGC/MS analysiBoswellia sacraantimicrobial activitybiologyTraditional medicine010405 organic chemistrylcsh:RM1-950Malassezia furfurFrankincensebiology.organism_classificationAntimicrobial0104 chemical sciencesBoswellia sacralcsh:Therapeutics. Pharmacology030104 developmental biologyInfectious DiseasesStaphylococcus aureusPseudomonas aeruginosaStaphylococcus aureuGC/MS analysisfrankincense essential oilAntibiotics
researchProduct

Persistence of Two Non-Saccharomyces Yeasts (Hanseniaspora and Starmerella) in the Cellar

2016

International audience; Different genera and/or species of yeasts present on grape berries, in musts and wines are widely described. Nevertheless, the community of non-Saccharomyces yeasts present in the cellar is still given little attention. Thus it is not known if the cellar is a real ecological niche for these yeasts or if it is merely a transient habitat for populations brought in by grape berries during the winemaking period. This study focused on three species of non-Saccharomyces yeasts commonly encountered during vinification: Starmerella bacillaris (synonymy with Candida zemplinina), Hanseniaspora guilliermondii and Hanseniaspora uvarum. More than 1200 isolates were identified at …

0301 basic medicineMicrobiology (medical)Grape berriesCerevisiaeWine yeast[ SDV.AEN ] Life Sciences [q-bio]/Food and Nutrition030106 microbiologyStarmerellalcsh:QR1-502StrainsCandida-stellataHanseniasporaMicrobiologySaccharomyceslcsh:MicrobiologyHanseniaspora03 medical and health sciences[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologycellarBotanyOriginal ResearchWinemakingDiversitybiologyfungifood and beveragespersistenceEnological propertiesbiology.organism_classificationSulfur-dioxideYeastCandida zemplininaYeast in winemaking[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologynon-Saccharomyces strainsStarmerellaHanseniaspora guilliermondiiAlcoholic fermentationPopulation-dynamicsFrontiers in Microbiology
researchProduct

Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on …

2017

Abstract Introduction The study objective was to evaluate the efficacy of different dosages of caspofungin in the treatment of invasive candidiasis and aspergillosis, in relation to the probability of pharmacokinetic/pharmacodynamic (PK/PD) target attainment, using modelling and Monte Carlo simulations in critically ill adult patients on continuous haemodiafiltration. Methods Critically ill adult patients on continuous venovenous haemodiafiltration treated with caspofungin were analysed. A population PK model was developed. Four caspofungin dosing regimens were simulated: the licensed regimen, 70 mg/day, 100 mg/day or 200 mg/day. A PK/PD target was defined as the ratio between the area unde…

0301 basic medicineMicrobiology (medical)MaleAntifungal AgentsCandida parapsilosisCritical Illness030106 microbiologyPopulationCandida glabrataHemodiafiltrationMicrobial Sensitivity TestsPharmacologyAspergillosis03 medical and health scienceschemistry.chemical_compoundEchinocandinsLipopeptides0302 clinical medicinePharmacokineticsCaspofunginCandida albicansMedicineHumansPharmacology (medical)Candidiasis Invasive030212 general & internal medicineDosingeducationAgedAged 80 and overInvasive Pulmonary Aspergillosiseducation.field_of_studyMaintenance dosebusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseRegimenInfectious DiseasesAspergilluschemistryPharmacodynamicsFemaleCaspofunginbusinessInternational journal of antimicrobial agents
researchProduct